Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

389 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
Tam CS, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S, Barr PM, Tedeschi A, Trentin L, Bannerji R, Jackson S, Kuss BJ, Moreno C, Szafer-Glusman E, Russell K, Zhou C, Ninomoto J, Dean JP, Wierda WG, Ghia P. Tam CS, et al. Among authors: ghia p. Blood. 2022 Jun 2;139(22):3278-3289. doi: 10.1182/blood.2021014488. Blood. 2022. PMID: 35196370 Free PMC article.
Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia.
Ten Hacken E, Sivina M, Kim E, O'Brien S, Wierda WG, Ferrajoli A, Estrov Z, Keating MJ, Oellerich T, Scielzo C, Ghia P, Caligaris-Cappio F, Burger JA. Ten Hacken E, et al. Among authors: ghia p. J Immunol. 2016 Sep 15;197(6):2522-31. doi: 10.4049/jimmunol.1600915. Epub 2016 Aug 17. J Immunol. 2016. PMID: 27534555 Free PMC article.
Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment.
Gounari M, Ntoufa S, Gerousi M, Vilia MG, Moysiadis T, Kotta K, Papakonstantinou N, Scarfò L, Agathangelidis A, Fonte E, Ranghetti P, Nenou A, Xochelli A, Coscia M, Tedeschi A, Stavroyianni N, Muzio M, Stamatopoulos K, Ghia P. Gounari M, et al. Among authors: ghia p. Leukemia. 2019 Apr;33(4):1030-1051. doi: 10.1038/s41375-018-0335-2. Epub 2019 Jan 3. Leukemia. 2019. PMID: 30607020 No abstract available.
IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia.
Scheffold A, Jebaraj BMC, Tausch E, Bloehdorn J, Ghia P, Yahiaoui A, Dolnik A, Blätte TJ, Bullinger L, Dheenadayalan RP, Li L, Schneider C, Chen SS, Chiorazzi N, Dietrich S, Seiffert M, Tannheimer S, Döhner H, Mertens D, Stilgenbauer S. Scheffold A, et al. Among authors: ghia p. Blood. 2019 Aug 8;134(6):534-547. doi: 10.1182/blood.2018881029. Epub 2019 Apr 22. Blood. 2019. PMID: 31010847 Free PMC article.
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S, Robak T, Kipps TJ, Schuh A, Moreno C, Furman RR, Burger JA, O'Dwyer M, Ghia P, Valentino R, Chang S, Dean JP, James DF, O'Brien SM. Coutre SE, et al. Among authors: ghia p. Blood Adv. 2019 Jun 25;3(12):1799-1807. doi: 10.1182/bloodadvances.2018028761. Blood Adv. 2019. PMID: 31196847 Free PMC article. Clinical Trial.
Inhibition of EZH2 and immune signaling exerts synergistic antitumor effects in chronic lymphocytic leukemia.
Chartomatsidou E, Ntoufa S, Kotta K, Rovida A, Akritidou MA, Belloni D, Ferrero E, Trangas T, Stavroyianni N, Anagnostopoulos A, Rosenquist R, Ghia P, Papakonstantinou N, Stamatopoulos K. Chartomatsidou E, et al. Among authors: ghia p. Blood Adv. 2019 Jun 25;3(12):1891-1896. doi: 10.1182/bloodadvances.2018030262. Blood Adv. 2019. PMID: 31227476 Free PMC article.
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.
Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, Bairey O, Hillmen P, Coutre SE, Devereux S, Grosicki S, McCarthy H, Simpson D, Offner F, Moreno C, Dai S, Lal I, Dean JP, Kipps TJ. Burger JA, et al. Among authors: ghia p. Leukemia. 2020 Mar;34(3):787-798. doi: 10.1038/s41375-019-0602-x. Epub 2019 Oct 18. Leukemia. 2020. PMID: 31628428 Free PMC article. Clinical Trial.
Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study.
Davids MS, Kuss BJ, Hillmen P, Montillo M, Moreno C, Essell J, Lamanna N, Nagy Z, Tam CS, Stilgenbauer S, Ghia P, Delgado J, Lustgarten S, Weaver DT, Youssoufian H, Jäger U. Davids MS, et al. Among authors: ghia p. Clin Cancer Res. 2020 May 1;26(9):2096-2103. doi: 10.1158/1078-0432.CCR-19-3061. Epub 2020 Jan 21. Clin Cancer Res. 2020. PMID: 31964785 Clinical Trial.
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.
Scarfò L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, Garcia-Marco JA, Hernández-Rivas JÁ, Mirás F, Baile M, Marquet J, Niemann CU, Reda G, Munir T, Gimeno E, Marchetti M, Quaglia FM, Varettoni M, Delgado J, Iyengar S, Janssens A, Marasca R, Ferrari A, Cuéllar-García C, Itchaki G, Špaček M, De Paoli L, Laurenti L, Levin MD, Lista E, Mauro FR, Šimkovič M, Van Der Spek E, Vandenberghe E, Trentin L, Wasik-Szczepanek E, Ruchlemer R, Bron D, De Paolis MR, Del Poeta G, Farina L, Foglietta M, Gentile M, Herishanu Y, Herold T, Jaksic O, Kater AP, Kersting S, Malerba L, Orsucci L, Popov VM, Sportoletti P, Yassin M, Pocali B, Barna G, Chiarenza A, Dos Santos G, Nikitin E, Andres M, Dimou M, Doubek M, Enrico A, Hakobyan Y, Kalashnikova O, Ortiz Pareja M, Papaioannou M, Rossi D, Shah N, Shrestha A, Stanca O, Stavroyianni N, Strugov V, Tam C, Zdrenghea M, Coscia M, Stamatopoulos K, Rossi G, Rambaldi A, Montserrat E, Foà R, Cuneo A, Ghia P. Scarfò L, et al. Among authors: ghia p. Leukemia. 2020 Sep;34(9):2354-2363. doi: 10.1038/s41375-020-0959-x. Epub 2020 Jul 9. Leukemia. 2020. PMID: 32647324 Free PMC article.
Reply to "CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report" Analysis of six hematological centers in Lombardy : On behalf of CLL commission of Lombardy Hematology Network (REL).
Reda G, Noto A, Cassin R, Zamprogna G, Borella C, Scarfò L, Farina L, Molteni A, Ghia P, Tedeschi A, Montillo M; Rete Ematologica Lombarda (REL) Clinical Network. Reda G, et al. Among authors: ghia p. Leukemia. 2020 Sep;34(9):2531-2532. doi: 10.1038/s41375-020-0966-y. Epub 2020 Aug 4. Leukemia. 2020. PMID: 32753689 Free PMC article. No abstract available.
389 results